慢性肺心病急性加重期患者川芎嗪注射液的应用研究  

Study of using tetramethylpyrazine in treating patients with chronic pulmonary heart disease at acute exacerbation stage

作　　者：陈学远[1] 黄春华[2] 陈斯宁[2] 黄美杏[2] 

机构地区：[1]广西医科大学,530021 [2]广西中医学院附属瑞康医院呼吸内科,530011

出　　处：《临床肺科杂志》2007年第7期706-707,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的研究慢性肺心病急性加重期患者应用川芎嗪注射液对其临床疗效及血管活性物质的影响。方法采取随机、对照试验方法,将60例慢性肺心病急性加重期患者随机分为川芎嗪治疗组和对照组,观察两组患者治疗前后临床疗效和血一氧化氮(NO)、内皮素-1(ET-1)的变化。结果川芎嗪治疗组临床疗效优于对照组。川芎嗪治疗组治疗后血NO升高、ET-1降低更为显著,与对照组治疗后比较有显著性差异(P<0.05)。结论川芎嗪治疗慢性肺心病急性加重期安全有效。其机制可能是通过选择性作用于肺血管,抑制ET-1而增加NO的合成与释放,从而降低肺动脉高压,改善患者心肺功能。Objective To study the effects of tetramethylpyrazine in clinical treatment and vasomotor in patients with chronic pulmonary heart disease during acute exacerbation stage. Method 60 cases of chronic pulmonary heart disease during acute exacerbation stage were randomly devided into tetramethylpyrazine treatment group and control group. The changes of clinical effect, plasmic nitricoxide （NO） and endothelin-1 （ ET-1 ） were measured before and after treatment. Results The clinical effective rate in the tetramethylpyrazine treatment group was better than that in the control group. Mter treatment, plasmic NO in the tetramethylpyrazine treatment group was higher than that in the control group, while ET-1 in the tetramethylpyrazine treatment group was lower than that in the control group. Conclusion It is effective and safe using tetramethylpyrazine in treating patients with chronic pulmonary heart disease during acute exacerbation stage. It is probably due to the mechanism of improving NO release and of decreasing ET - 1 release from lung vascular endothelial cells, thus decreasing pulmonary hypertention.

关 键 词：肺心病 川芎嗪 一氧化氮 内皮素 

分 类 号：R541.5[医药卫生—心血管疾病]